Accelerated corneal crosslinking (CXL) procedure
Accelerated treatment improves keratoconus, BCVA with less pain at 24 months


Howard Larkin
Published: Wednesday, January 25, 2017

Accelerated transepithelial CXL was safe and effective for progressive keratoconus with a reduced rate of complications and operative and postoperative discomfort related to epithelial removalUVA 370nm was applied at 30mW/cm² with continued application of 0.25% riboflavin for three minutes, delivering a total dose of 5.4J/cm². An optical antibiotic ointment ofloxacin 0.3% and bandage were applied for one day, and antibiotic drop 1.5% levofloxacin and corticosteroid 0.1% fluorometholone applied topically for one week. No intraoperative or postoperative complications were observed, and all 21 eyes completed follow-up. At 24 months, mean BCVA improved from about 0.22 logMAR to about 0.08 (P=0.2). Kmax declined from a mean of about 59 dioptres to 55.5 (P=0.003) and average K from about 52 to 49 dioptres (P=0.02). Thinnest corneal readings also dropped significantly though central corneal thickness remained stable, as did endothelial cell density and intraocular pressure, Dr Aixinjueluo reported. “Accelerated transepithelial CXL was safe and effective for progressive keratoconus with a reduced rate of complications and operative and postoperative discomfort related to epithelial removal,” she concluded. Wei Aixinjueluo: waixinjueluo@yahoo.co.jp
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.